RayKnowChina Research Map
Shortlist0

ShenyangChina Medical University (Shenyang)

Shengjing Hospital of China Medical University

中国医科大学附属盛京医院

Listed for 31 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shengjing Hospital of China Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led
  2. Hepatocellular carcinoma肝细胞癌60 papers led1 open trial led
  3. Stomach cancer胃癌27 papers led
  4. Hepatoblastoma肝母细胞瘤0 papers led
  5. Retinoblastoma视网膜母细胞瘤2 papers led
  6. Osteosarcoma骨肉瘤25 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤6 papers led
  8. Neuroblastoma神经母细胞瘤10 papers led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤7 papers led
  11. Haemophilia A血友病 A0 papers led
  12. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
  13. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  15. IgG4-related diseaseIgG4相关性疾病3 papers led
  16. Myasthenia gravis重症肌无力4 papers led
  17. Wilson disease肝豆状核变性(Wilson 病)2 papers led
  18. Biliary atresia胆道闭锁4 papers led
  19. Takayasu arteritis大动脉炎1 paper led
  20. Idiopathic pulmonary fibrosis特发性肺纤维化5 papers led
  21. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  22. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  23. Pompe disease庞贝病0 papers led
  24. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  25. Behçet disease白塞病1 paper led
  26. IgA nephropathyIgA 肾病4 papers led
  27. Osteogenesis imperfecta成骨不全症1 paper led
  28. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  29. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  30. Congenital diaphragmatic hernia先天性膈疝0 papers led
  31. Hirschsprung disease先天性巨结肠0 papers led

Not listed for: Oesophageal squamous cell carcinoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Fanconi anaemia, Moyamoya disease, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Fabry disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 0020242025: 112025

2 hospitals in Shenyang for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesSide effects & quality of lifeImaging & AI
Departments in papersENT / head & neck surgery

Over half of these papers are lab or animal studies.

Papers it led5
  1. Neuron-like macrophage differentiation via the APOE-TREM2 axis contributes to chronic pain in nasopharyngeal carcinoma.2025Cell biology and toxicologyFree full text
  2. Extracellular vesicles derived from paclitaxel-sensitive nasopharyngeal carcinoma cells deliver miR-183-5p and impart paclitaxel sensitivity through a mechanism involving P-gp.2023Cell biology and toxicology
  3. Identification of markers for predicting prognosis and endocrine metabolism in nasopharyngeal carcinoma by miRNA-mRNA network mining and machine learning.2023Frontiers in endocrinologyFree full text
  4. Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: A meta-analysis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  5. The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.2022Minerva medica
All its trials on ClinicalTrials.gov, any status1
  1. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10
More papers found outside PubMed (not counted)2
  1. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncologyconference-abstract
  2. Targeting platelet/endothelial cell adhesion molecule 1 enhances cisplatin sensitivity of human nasopharyngeal carcinoma cells exposed to ionizing radiation2021Internatuinal Journal of Radiation Researcharticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 60 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
60
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 9920212022: 141420222023: 6620232024: 212120242025: 992025

4 hospitals in Shenyang for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07768085

    Age 18 years to Not stated (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  2. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  3. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  4. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  5. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led60
  1. Tumor stiffness as an imaging biomarker of tyrosine kinase inhibitor response: A preclinical study.2026Magnetic resonance imaging
  2. Oxytocin Receptor Regulates the Hippo/YAP Axis to Drive Hepatocarcinogenesis.2025Cancer researchFree full text
  3. SERPINA1 drives TACE resistance in hepatocellular carcinoma by competitively binding ITGB3 to block ITCH-mediated ubiquitination and degradation.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  4. Effect of calcium concentration on metastasis of hepatocellular carcinoma cells cultured in alginate gel beads.2025Colloids and surfaces. B, Biointerfaces
  5. Prognostic Value of the PET/CT-Derived Maximum Standardized Uptake Value Combined with the Neutrophil-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy.2025Current oncology (Toronto, Ont.)Free full text
  6. Exploring the association between air pollution and the incidence of liver cancers.2025Ecotoxicology and environmental safety
  7. Development and validation of a new prognostic tool for hepatocellular carcinoma undergoing resection: The Weighted Alpha-Fetoprotein Tumor Burden Score (WATS).2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  8. Mechanisms of tumor heterogeneity in TACE-resistant liver cancer: Insights from single-cell and whole-exome sequencing.2025Hepatology communicationsFree full text
  9. Iodixanol-Loaded Thermosensitive Liposomes: A Novel Imaging Contrast Agent for Precision Hepatocellular Carcinoma Ablation.2025Molecular pharmaceutics
  10. OTUB1 antagonizes TRIM21 to induce deubiquitination of SPHK1 and promote the progression of hepatocellular carcinoma.2025Oncogene
  11. NETosis in tumour microenvironment of liver: From primary to metastatic hepatic carcinoma.2024Ageing research reviews
  12. Predictive nomograms based on gamma-glutamyl transpeptidase to prealbumin ratio for prognosis of hepatocellular carcinoma patients without microvascular invasion.2024BMC cancerFree full text
  13. BAP18 acting as a novel peroxisome proliferator-activated receptor α co-regulator contributes to hepatocellular carcinoma progression.2024Biochimica et biophysica acta. Molecular basis of disease
  14. Hepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation: Novel insights from single-cell RNA sequencing and spatial transcriptomics analyses.2024Cancer letters
  15. A Novel Prognostic Nomogram Based on TIGIT and NKG2A Can Predict Relapse-Free Survival of Hepatocellular Carcinoma After Hepatectomy.2024Cancer medicineFree full text
  16. Proteome microarray identifies autoantibody biomarkers for diagnosis of hepatitis B-related hepatocellular carcinoma.2024Clinica chimica acta; international journal of clinical chemistry
  17. Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application.2024Clinical and translational medicineFree full text
  18. Decoding the roles of heat shock proteins in liver cancer.2024Cytokine & growth factor reviews
  19. The roles of nuclear receptors in cholesterol metabolism and reverse cholesterol transport in nonalcoholic fatty liver disease.2024Hepatology communicationsFree full text
  20. Comment on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".2024International journal of cancer
  21. CHMP3 promotes the progression of hepatocellular carcinoma by inhibiting caspase‑1‑dependent pyroptosis.2024International journal of oncologyFree full text
  22. Identification of PPAR-related differentially expressed genes liver hepatocellular carcinoma and construction of a prognostic model based on data analysis and molecular docking.2024Journal of cellular and molecular medicineFree full text
  23. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.2024Journal of cellular and molecular medicineFree full text
  24. The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.2024Journal of cellular and molecular medicineFree full text
  25. Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors.2024Journal of natural products
  26. Screening of Cancer-Specific Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma Based on a Proteome Microarray.2024Molecular & cellular proteomics : MCPFree full text
  27. STAMBPL1, transcriptionally regulated by SREBP1, promotes malignant behaviors of hepatocellular carcinoma cells via Wnt/β-catenin signaling pathway.2024Molecular carcinogenesis
  28. HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.2024Molecular carcinogenesis
  29. Nicotinamide mononucleotide induces autophagy and ferroptosis via AMPK/mTOR pathway in hepatocellular carcinoma.2024Molecular carcinogenesis
  30. Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  31. Role of albumin-bilirubin score in non-malignant liver disease.2024World journal of gastroenterologyFree full text
  32. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.2023AgingFree full text
  33. VEZF1, destabilized by STUB1, affects cellular growth and metastasis of hepatocellular carcinoma by transcriptionally regulating PAQR4.2023Cancer gene therapy
  34. PI3K δ inhibitor PI-3065 induces apoptosis in hepatocellular carcinoma cells by targeting survivin.2023Chemico-biological interactions
  35. LncRNA AC012360.1 facilitates growth and metastasis by regulating the miR-139-5p/LPCAT1 axis in hepatocellular carcinoma.2023Environmental toxicology
  36. Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  37. Circulating Bile Acids as Biomarkers for Disease Diagnosis and Prevention.2023The Journal of clinical endocrinology and metabolism
  38. Development and validation of a 4-lncRNA combined prediction model for patients with hepatocellular carcinoma.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  39. p53 m6A modulation sensitizes hepatocellular carcinoma to apatinib through apoptosis.2022Apoptosis : an international journal on programmed cell death
  40. An extraction from Trametes robiniophila Murr. (Huaier) inhibits non-small cell lung cancer proliferation via targeting to epidermal growth factor receptor.2022BioengineeredFree full text
  41. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.2022Cancer medicineFree full text
  42. Development and validation of an immune-related prognosis signature associated with hypoxia and ferroptosis in hepatocellular carcinoma.2022Cancer medicineFree full text
  43. microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway.2022Cell cycle (Georgetown, Tex.)Free full text
  44. LncRNA ILF3-AS1 promotes cell migration, invasion and EMT process in hepatocellular carcinoma via the miR-628-5p/MEIS2 axis to activate the Notch pathway.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  45. Therapeutic efficacy of microwave coagulation versus liver resection for hepatocellular carcinoma within the Milan criteria: A propensity score matching analysis.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  46. Identification of serum glycobiomarkers for Hepatocellular Carcinoma using lectin microarrays.2022Frontiers in immunologyFree full text
  47. Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-κB pathway.2022International journal of pharmaceutics
  48. Research progress of gut microbiota in hepatocellular carcinoma.2022Journal of clinical laboratory analysisFree full text
  49. Correlation Between Contrast-Enhanced Ultrasound and Immune Response of Distant Hepatocellular Carcinoma After Radiofrequency Ablation in a Murine Model.2022Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  50. Resina Draconis extract exerts anti-HCC effects through METTL3-m6A-Survivin axis.2022Phytotherapy research : PTR
  51. AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy.2022TheranosticsFree full text
  52. PAQR4 promotes the development of hepatocellular carcinoma by activating PI3K/AKT pathway.2021Acta biochimica et biophysica Sinica
  53. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.2021Anti-cancer drugsFree full text
  54. Applying arterial enhancement fraction (AEF) texture features to predict the tumor response in hepatocellular carcinoma (HCC) treated with Transarterial chemoembolization (TACE).2021Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  55. USP14 maintains HIF1-α stabilization via its deubiquitination activity in hepatocellular carcinoma.2021Cell death & diseaseFree full text
  56. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.2021Expert opinion on drug delivery
  57. Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma.2021Food & function
  58. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  59. A novel therapeutic strategy for hepatocellular carcinoma: Immunomodulatory mechanisms of selenium and/or selenoproteins on a shift towards anti-cancer.2021International immunopharmacology
  60. The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma.2021Life sciences
Chinese-language papers (not in the count)4
  1. [Progress on the research of liver diseases in 2023].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Antiviral therapy for chronic hepatitis B: the imperative to move from scaling-up treatment to full treatment].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Progress on the research of liver diseases in 2022].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status14
  1. Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CTNot yet recruitingNCT07768085Lead sponsorN/AStart 2026-08
  2. Interventional AI-Human Collaboration for Liver Tumor DiagnosisCompletedNCT07153783Lead sponsorN/AStart 2025-09
  3. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  4. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  5. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  6. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  7. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  8. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  9. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  10. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Study sitePhase 3Start 2021-04
  11. Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCCStatus unknownNCT04920214Study siteStart 2021-01
  12. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  13. Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCCStatus unknownNCT04157140Study sitePhase 2Start 2019-11
  14. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular CarcinomaCompletedNCT03113955Study siteN/AStart 2017-10

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 27 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
27
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 6620222023: 5520232024: 9920242025: 332025

5 hospitals in Shenyang for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicineMedical oncology
Papers it led27
  1. Prognostic performance of examined lymph nodes, lymph node ratio, and positive lymph nodes in gastric cancer: a competing risk model study.2025Frontiers in endocrinologyFree full text
  2. Hypoxia-associated genes as predictors of outcomes in gastric cancer: a genomic approach.2025Frontiers in immunologyFree full text
  3. Clinical and prognostic significance of m6A hypomethylation and IGF2BP3 overexpression in gastric cancer: an integrated epigenomic-transcriptomic analysis.2025Human genomicsFree full text
  4. Radiomics analysis in predicting vascular invasion in gastric cancer based on enhanced CT: a preliminary study.2024BMC cancerFree full text
  5. Helicobacter pylori infection induces POU5F1 upregulation and SPP1 activation to promote chemoresistance and T cell inactivation in gastric cancer cells.2024Biochemical pharmacology
  6. Dysregulation of autophagy in gastric carcinoma: Pathways to tumor progression and resistance to therapy.2024Cancer letters
  7. Advancing gastric cancer treatment: nanotechnology innovations and future prospects.2024Cell biology and toxicologyFree full text
  8. E3 ubiquitin ligase RNF180 impairs IPO4/SOX2 complex stability and inhibits SOX2-mediated malignancy in ovarian cancer.2024Cellular signalling
  9. OTUD7B deubiquitinates and stabilizes YAP1 to upregulate NUAK2 expression, thus accelerating gastric cancer procession.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  10. Cancer cell membrane-camouflaged curcumin nanoparticles trigger ferroptosis for accurate gastric cancer therapy.2024European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  11. EUS-guided direct removal of a foreign body embedded in the stomach after failure of endoscopic submucosal dissection (with video).2024Gastrointestinal endoscopy
  12. Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression.2024International journal of clinical oncology
  13. Long noncoding RNA PSMA3-AS1 functions as a competing endogenous RNA to promote gastric cancer progression by regulating the miR-329-3p/ALDOA axis.2023Biology directFree full text
  14. Metabolic codependencies in the tumor microenvironment and gastric cancer: Difficulties and opportunities.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  15. FTO demethylates m6A modifications in CDKAL1 mRNA and promotes gastric cancer chemoresistance by altering mitochondrial dynamics.2023Clinical and experimental pharmacology & physiology
  16. Tumor-promoting action of ubiquitin protease 43 in gastric cancer progression through deubiquitination and stabilization of stress-inducible phosphoprotein 1.2023Experimental cell research
  17. Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma.2023Frontiers in immunologyFree full text
  18. The necessarity of treatment for small gastric subepithelial tumors (1-2 cm) originating from muscularis propria: an analysis of 972 tumors.2022BMC gastroenterologyFree full text
  19. "PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody": Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of ErbB2-Overexpressing Gastric Cancer Cells.2022Drug design, development and therapyFree full text
  20. Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma.2022European journal of medical researchFree full text
  21. Cruciferous vegetable consumption and multiple health outcomes: an umbrella review of 41 systematic reviews and meta-analyses of 303 observational studies.2022Food & function
  22. Comparison between the widely used magnetically controlled capsule gastroscopy and conventional gastroscopy: a meta-analysis.2022Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  23. Efficacy of endoscopic ultrasound in the evaluation of small gastrointestinal stromal tumors.2022World journal of gastroenterologyFree full text
  24. A novel pN3 gastric cancer staging system with superior prognostic utility based upon the examination of over 31 lymph nodes: a propensity score-matching analysis.2021BMC gastroenterologyFree full text
  25. Bioinformatic Analysis Identified Potentially Prognostic Long Noncoding RNAs and MicroRNAs for Gastric Cancer.2021BioMed research internationalFree full text
  26. Medical image recognition and segmentation of pathological slices of gastric cancer based on Deeplab v3+ neural network.2021Computer methods and programs in biomedicine
  27. Endoscopic full-thickness resection using an over-the-scope device: A prospective study.2021World journal of gastroenterologyFree full text
All its trials on ClinicalTrials.gov, any status5
  1. Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric CancerStatus unknownNCT05070598Lead sponsorPhase 2Start 2021-09
  2. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  3. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Study sitePhase 1Start 2024-03
  4. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  5. A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric CancerTerminatedNCT01967875Study sitePhase 2Start 2013-07

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shenyang for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Shenyang for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 25 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
25
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 9920232024: 3320242025: 552025

9 hospitals in Shenyang for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsMedical oncologyNeurosurgerySurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led25
  1. CPE/HYOU1 axis-activated Hippo-YAP signaling pathway suppresses PANoptosis to facilitate osteosarcoma progression.2026Cancer letters
  2. NRF1 Transcriptionally Regulates USP1-Mediated Deubiquitination of AURKA to Facilitate Osteosarcoma Progression.2026Molecular biotechnology
  3. GALNT6, transcriptionally inhibited by KLF9, promotes osteosarcoma progression by increasing EFEMP1 expression via O-glycosylation modification.2025Biochimica et biophysica acta. Molecular cell research
  4. Identifying KDM5B as the synthetic lethal target of KMT2D-mutated osteosarcoma.2025Chemico-biological interactions
  5. Neurotrophic factors as double-edged swords in osteosarcoma: drivers of tumour growth and immune remodelling.2025Frontiers in immunology
  6. WDR3 undergoes phase separation to mediate the therapeutic mechanism of Nilotinib against osteosarcoma.2025Journal of experimental & clinical cancer research : CR
  7. Role of long noncoding RNAs in the regulation of epithelial‑mesenchymal transition in osteosarcoma (Review).2025Oncology reports
  8. Mitochondria in skeletal system-related diseases.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. Single-cell RNA sequencing reveals the communications between tumor microenvironment components and tumor metastasis in osteosarcoma.2024Frontiers in immunology
  10. FBXO22 promotes osteosarcoma progression via regulation of FOXO1 for ubiquitination and degradation.2024Journal of cellular and molecular medicine
  11. Metastasis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma.2023Aging
  12. Clinical significance and immune landscape of a novel ferroptosis-related prognosis signature in osteosarcoma.2023BMC cancer
  13. HTRA3 transcriptionally inhibited by FOXP1 suppresses tumorigenesis of osteosarcoma via the PTEN/PI3K/AKT pathway.2023Biochimica et biophysica acta. Molecular cell research
  14. Chitosan targets PI3K/Akt/FoxO3a axis to up-regulate FAM172A and suppress MAPK/ERK pathway to exert anti-tumor effect in osteosarcoma.2023Chemico-biological interactions
  15. HIF-1α/MMP-9 promotes spinal cord central sensitization in rats with bone cancer pain.2023European journal of pharmacology
  16. Current status and future challenges of CAR-T cell therapy for osteosarcoma.2023Frontiers in immunology
  17. Targeted therapy for osteosarcoma: a review.2023Journal of cancer research and clinical oncology
  18. ARHGAP44-mediated regulation of the p53/C-myc/Cyclin D1 pathway in modulating the malignant biological behavior of osteosarcoma cells.2023Journal of orthopaedic surgery and research
  19. Primary Intracranial Ewing Sarcoma Invading the Superior Sagittal Sinus with EWSR1-FLI1 Gene Fusion and EWSR1 Gene Mutation: A Case Report and Literature Review.2023World neurosurgery
  20. SNHG1 functions as an oncogenic lncRNA and promotes osteosarcoma progression by up-regulating S100A6 via miR-493-5p.2022Acta biochimica et biophysica Sinica
  21. KDM3A-mediated SP1 activates PFKFB4 transcription to promote aerobic glycolysis in osteosarcoma and augment tumor development.2022BMC cancer
  22. UHRF1 associated with osteogenic differentiation of MSCs contributes to osteosarcoma progression and has clinical prognostic impact in osteosarcoma.2022Critical reviews in eukaryotic gene expression
  23. MicroRNA-519d-3p antagonizes osteosarcoma resistance against cisplatin by targeting PD-L1.2022Molecular carcinogenesis
  24. Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis.2021Mediators of inflammation
  25. circHIPK3 promotes proliferation and migration and invasion via regulation of miR‑637/HDAC4 signaling in osteosarcoma cells.2021Oncology reports
Earlier papers (2016–2020)23
  1. Notch-1 promotes the malignant progression of osteosarcoma through the activation of cell division cycle 20.2020Aging
  2. Patrolling monocytes inhibit osteosarcoma metastasis to the lung.2020Aging
  3. Activating transcription factor 6 (ATF6) negatively regulates Polo-like kinase 4 expression via recruiting C/EBPβ to the upstream-promoter during ER stress.2020Biochimica et biophysica acta. Gene regulatory mechanisms
  4. MiR-421 promotes the development of osteosarcoma by regulating MCPIP1 expression.2020Cancer biology & therapy
  5. Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell.2020Cell cycle (Georgetown, Tex.)
  6. Long noncoding RNA lncARSR confers resistance to Adriamycin and promotes osteosarcoma progression.2020Cell death & disease
  7. LINC01128 regulates the development of osteosarcoma by sponging miR-299-3p to mediate MMP2 expression and activating Wnt/β-catenin signalling pathway.2020Journal of cellular and molecular medicine
  8. Identification of 9-Gene Epithelial-Mesenchymal Transition Related Signature of Osteosarcoma by Integrating Multi Cohorts.2020Technology in cancer research & treatment
  9. Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma.2019Aging
  10. miR-548d-3p inhibits osteosarcoma by downregulating KRAS.2019Aging
  11. MicroRNA-506-3p initiates mesenchymal-to-epithelial transition and suppresses autophagy in osteosarcoma cells by directly targeting SPHK1.2019Bioscience, biotechnology, and biochemistry
  12. MiR-216b inhibits osteosarcoma cell proliferation, migration, and invasion by targeting Forkhead Box M1.2019Journal of cellular biochemistry
  13. Zoledronic acid modulates human osteosarcoma cells proliferation via GSK-3β activation.2019Neoplasma
  14. Naringin targets Zeb1 to suppress osteosarcoma cell proliferation and metastasis.2018Aging
  15. MicroRNA-506-3p inhibits osteosarcoma cell proliferation and metastasis by suppressing RAB3D expression.2018Aging
  16. MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling.2018Biochemical and biophysical research communications
  17. miR-503 is down-regulated in osteosarcoma and suppressed MG63 proliferation and invasion by targeting VEGFA/Rictor.2018Cancer biomarkers : section A of Disease markers
  18. Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo.2018Experimental cell research
  19. Oleanolic acid induces osteosarcoma cell apoptosis by inhibition of Notch signaling.2018Molecular carcinogenesis
  20. Combination of subxiphoid and intercostal uniportal video-assisted thoracoscopic surgery for bilateral lung lesions: report of two cases and review of the literature.2017Postgraduate medicine
  21. CHOP negatively regulates Polo-like kinase 2 expression via recruiting C/EBPα to the upstream-promoter in human osteosarcoma cell line during ER stress.2017The international journal of biochemistry & cell biology
  22. Expression and function of microRNA-497 in human osteosarcoma.2016Molecular medicine reports
  23. Noscapine targets EGFRp-Tyr1068 to suppress the proliferation and invasion of MG63 cells.2016Scientific reports

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 6 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.1%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 3320232024: 0020242025: 002025

3 hospitals in Shenyang for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led6
  1. Characterization of a Human Gastrointestinal Stromal Tumor Cell Line Established by SV40LT-Mediated Immortalization.2023International journal of molecular sciences
  2. Chinese Pedigree with Hereditary Gastrointestinal Stromal Tumors: A Case Report and Literature Review.2023International journal of molecular sciences
  3. Predictive Value of a Radiomics Nomogram Model Based on Contrast-Enhanced Computed Tomography for KIT Exon 9 Gene Mutation in Gastrointestinal Stromal Tumors.2023Technology in cancer research & treatment
  4. Retrospective study of the clinicopathological characteristics and prognostic factors of gastrointestinal stromal tumors in Chinese patients.2022Annals of diagnostic pathology
  5. The necessarity of treatment for small gastric subepithelial tumors (1-2 cm) originating from muscularis propria: an analysis of 972 tumors.2022BMC gastroenterologyFree full text
  6. Efficacy of endoscopic ultrasound in the evaluation of small gastrointestinal stromal tumors.2022World journal of gastroenterologyFree full text
Earlier papers (2016–2020)4
  1. Laparoscopic transgastric resection for intraluminal gastric gastrointestinal stromal tumors located at the posterior wall and near the gastroesophageal junction.2019Asian journal of surgery
  2. Transvaginal excision of rectal stromal tumors: case reports and a literature review.2019World journal of surgical oncology
  3. Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.2018Journal of biosciences
  4. Clinical and prognostic significance of Raf kinase inhibitory protein expression in gastrointestinal stromal tumors.2018World journal of gastroenterology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 10 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 1120232024: 1120242025: 332025

6 hospitals in Shenyang for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurosurgeryMedical oncology

Over half of these papers are lab or animal studies.

Papers it led10
  1. Chronic diarrhea related to neuroblastoma: the important role of vasoactive intestinal peptide in tumor pathology and survival.2025BMC cancer
  2. Silencing YTHDF2 Induces Apoptosis of Neuroblastoma Cells In a Cell Line-Dependent Manner via Regulating the Expression of DLK1.2025Molecular neurobiology
  3. Pharmacologically Targeting Ferroptosis and Cuproptosis in Neuroblastoma.2025Molecular neurobiology
  4. SESN1 functions as a new tumor suppressor gene via Toll-like receptor signaling pathway in neuroblastoma.2024CNS neuroscience & therapeutics
  5. Ginsenoside Rh2 inhibits CBP/p300-mediated FOXO3a acetylation and epilepsy-induced oxidative damage via the FOXO3a-KEAP1-NRF2 pathway.2023European journal of pharmacology
  6. Acute left heart failure with pulmonary edema during resection of pediatric neuroblastoma: case report.2022Brazilian journal of anesthesiology (Elsevier)
  7. Opsoclonus-myoclonus syndrome associated with neuroblastoma: Insights into antitumor immunity.2022Pediatric blood & cancer
  8. Analysis and identification of novel biomarkers involved in neuroblastoma via integrated bioinformatics.2021Investigational new drugs
  9. Downregulation of fibronectin 1 attenuates ATRA-induced inhibition of cell migration and invasion in neuroblastoma cells.2021Molecular and cellular biochemistry
  10. Integrated Microarray to Identify the Hub miRNAs and Constructed miRNA-mRNA Network in Neuroblastoma Via Bioinformatics Analysis.2021Neurochemical research
Earlier papers (2016–2020)5
  1. Downregulation of PIF1, a potential new target of MYCN, induces apoptosis and inhibits cell migration in neuroblastoma cells.2020Life sciences
  2. P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).2018Apoptosis : an international journal on programmed cell death
  3. Intracranial immature teratoma invading the nasal cavity mimicking olfactory neuroblastoma: A case report.2018Medicine
  4. Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells.2017Molecular and cellular biochemistry
  5. Proteome and Acetylome Analysis Identifies Novel Pathways and Targets Regulated by Perifosine in Neuroblastoma.2017Scientific reports

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Shenyang for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 7 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 2220242025: 332025

2 hospitals in Shenyang for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  3. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  4. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  5. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsDiagnosis, MRD & riskBispecific & antibody drugs
Papers it led7
  1. The diagnostic and therapeutic potential of multiple myeloma-associated circular RNAs.2025Experimental hematology
  2. Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma.2025Nature communicationsFree full text
  3. A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast.2025Scientific reportsFree full text
  4. MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.2024Journal of experimental & clinical cancer research : CRFree full text
  5. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.2024The New England journal of medicineRCT
  6. Coexistence of plasma cell neoplasia and myelodysplastic syndrome with excess blasts: case reports and literature review.2021Annals of palliative medicine
  7. MicroRNA miR-188-5p as a mediator of long non-coding RNA MALAT1 regulates cell proliferation and apoptosis in multiple myeloma.2021BioengineeredFree full text
Chinese-language papers (not in the count)2
  1. [Research Advances in Multiple Myeloma with Chromosome 1q21 Amplification].2022Zhongguo shi yan xue ye xue za zhi
  2. [Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib].2021Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status21
  1. Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple MyelomaStatus unknownNCT05006469Lead (inferred)Phase 3Start 2021-06
  2. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  5. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  6. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  7. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  8. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  9. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05719701Study sitePhase 1/Phase 2Start 2023-03
  10. Study of 3D189 in Patients With Hematologic MalignanciesCompletedNCT05320809Study sitePhase 1Start 2022-08
  11. Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple MyelomaActive, not recruitingNCT05363800Study sitePhase 1Start 2022-06
  12. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  13. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruitingNCT04684108Study sitePhase 1Start 2021-11
  14. A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190Study siteStart 2021-10
  15. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  16. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  17. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04557098Study sitePhase 2Start 2020-09
  18. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  19. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  20. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  21. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Shenyang for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shenyang for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Shenyang for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

2 hospitals in Shenyang for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisPregnancy, children, older adults
Departments in papersNeurologyPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 3 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

2 hospitals in Shenyang for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesKidney, retroperitoneum & vesselsLung & chestTreatment & relapse
Departments in papersGastroenterology / hepatologyNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 222025

2 hospitals in Shenyang for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic & complement drugsStandard immunotherapyAntibodies & diagnosis
Departments in papersNeurologyPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 2 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Shenyang for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Diagnosis & copper testsChildren
Departments in papersPediatricsNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 4 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 1.9%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 002025

1 hospital in Shenyang for biliary atresia28 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesScreening & diagnosisDisease mechanisms
Departments in papersPediatricsRadiology / nuclear medicine
Papers it led4
  1. Polymeric immunoglobulin receptor promotes Th2 immune response in the liver by increasing cholangiocytes derived IL-33: a diagnostic and therapeutic biomarker of biliary atresia.2024EBioMedicineFree full text
  2. Dysmorphic Gallbladder Found on Prenatal Ultrasound as a Hint for Biliary Atresia.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  3. Prediction of Fetal Biliary Atresia Based on Second and Third-Trimester Ultrasound Characteristics.2023Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  4. Human poliovirus receptor contributes to biliary atresia pathogenesis by exacerbating natural-killer-cell-mediated bile duct injury.2022Liver international : official journal of the International Association for the Study of the Liver
Chinese-language papers (not in the count)1
  1. [New advances in the diagnosis and treatment of biliary atresia].2022Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
More papers found outside PubMed (not counted)1
  1. Predicting the outcomes of Kasai portoenterostomy for biliary atresia: a cohort study2022medRxivpreprint

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Shenyang for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 5 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 112025

7 hospitals in Shenyang for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePediatrics

Over half of these papers are lab or animal studies.

Papers it led5
  1. PLAC8 attenuates pulmonary fibrosis and inhibits apoptosis of alveolar epithelial cells via facilitating autophagy.2025Communications biology
  2. SCARF2 is a target for chronic obstructive pulmonary disease: Evidence from multi-omics research and cohort validation.2024Aging cell
  3. MICALL2 participates in the regulation of epithelial-mesenchymal transition in alveolar epithelial cells - Potential roles in pulmonary fibrosis.2023Archives of biochemistry and biophysics
  4. Downregulation of a potential therapeutic target NPAS2, regulated by p53, alleviates pulmonary fibrosis by inhibiting epithelial-mesenchymal transition via suppressing HES1.2023Cellular signalling
  5. Global research hotspots and research trends on idiopathic pulmonary fibrosis: a bibliometric and visualization analysis.2021Annals of palliative medicine
Earlier papers (2016–2020)2
  1. Inhibition of miR-182-5p attenuates pulmonary fibrosis via TGF-β/Smad pathway.2020Human & experimental toxicology
  2. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.2020Therapeutic advances in respiratory disease
All its trials on ClinicalTrials.gov, any status5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  3. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  4. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  5. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Shenyang for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Shenyang for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05824169

    Age 0 months to 6 months (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenyang, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 PatientsRecruitingNCT05824169Study sitePhase 1/Phase 2Start 2023-02
  2. Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921Study siteStart 2021-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shenyang for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Research advances in the diagnosis and treatment of Pompe disease].2018Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Shenyang for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Prenatal risk assessment of Xp21.1 duplication involving the DMD gene by optical genome mapping.2024Life science alliance
Chinese-language papers (not in the count)1
  1. [Expert consensus on the genetic counseling for Dystrophinopathies].2024Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)2
  1. Usefulness of speckle-tracking echocardiography for early detection in children with Duchenne muscular dystrophy: a meta-analysis and trial sequential analysis.2020Cardiovascular ultrasound
  2. [Comparison analysis of muscle enzymes in children with myocarditis and Duchene/Becker muscular dystrophy].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Shenyang for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Shenyang for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPediatrics
Papers it led4
  1. Single-Cell Analysis of Endothelial Cell Injury in IgA Nephropathy.2025Immunity, inflammation and disease
  2. Immunoglobulin a nephropathy as the first clinical presentation of Wilson disease: a case report and literature review.2021BMC gastroenterologyFree full text
  3. Co-occurrence of IgA nephropathy and IgG4-Tubulointersitial nephritis effectively treated with tacrolimus: a case report.2021BMC nephrologyFree full text
  4. Glomerular galactose-deficient IgA1 detected in donor-derived and recurrent IgA nephropathy.2021Transplant international : official journal of the European Society for Organ Transplantation
Earlier papers (2016–2020)3
  1. Urine markers of podocyte dysfunction: a review of podocalyxin and nephrin in selected glomerular diseases.2018Biomarkers in medicine
  2. Risk alleles for IgA nephropathy-associated SNPs conferred completely opposite effects to idiopathic membranous nephropathy in Chinese Han.2017Immunologic research
  3. The Association of rs1047763 and rs1008898 of C1GALT1 with IgA Nephropathy Risk: A Global Meta-Analysis.2017Monoclonal antibodies in immunodiagnosis and immunotherapy
All its trials on ClinicalTrials.gov, any status4
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Shenyang for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. X-linked osteogenesis imperfecta accompanied by patent ductus arteriosus: a case with a novel splice variant in PLS3.2022World journal of pediatrics : WJP
Chinese-language papers (not in the count)1
  1. [Identification of pathogenic variant and preimplantation genetic testing for a Chinese family affected with osteogenesis imperfecta].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)1
  1. [Phenotype-genotype analysis and detection of gene variant in six families with osteogenesis imperfecta].2020Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shenyang for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis.2016World journal of gastroenterology
All its trials on ClinicalTrials.gov, any status1
  1. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisActive, not recruitingNCT06174402Study sitePhase 2/Phase 3Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Shenyang for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shenyang for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shenyang for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中国医科大学附属盛京医院

Shengjing Hospital of China Medical University

沈阳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Shengjing Hospital; ShengJing Hospital of China Medical University; China Medical University Shengjing Hospital; Shengjing Hospital Affiliated to China Medical University; Affiliated Shengjing Hospital of China Medical University; Affiliated Shengjing Hospital; China Medical University Affiliated ShengJing Hospital; Sheng Jing Hospital

Suggest a correctionDownload the data